Emily Leongini Featured in Interview on FDA’s Role in the Cannabis Industry
In an interview with Dope Magazine, Food and Drug associate Emily Leongini discusses how the US Food and Drug Administration (FDA) is currently responding to the proliferation of state-legalized cannabis and how that could impact the growing cannabis industry. Emily notes that cannabis touches a wide variety of products traditionally regulated by FDA, including food, drugs, and dietary supplements. Yet, with only a few exceptions, FDA has largely deferred to the Drug Enforcement Administration (DEA), given marijuana’s Schedule I status. When asked about the pending application for the first plant-derived cannabinoid drug, Emily explains that, if approved by FDA, DEA would likely move the drug’s active ingredient (plant-derived cannabidiol (CBD)) from Schedule I to a lower schedule, which could potentially impact the burgeoning CBD industry.
Click here to read the full interview.